Literature DB >> 17692575

Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides.

Noha Nafee1, Sebastian Taetz, Marc Schneider, Ulrich F Schaefer, Claus-Michael Lehr.   

Abstract

Cationically modified poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles have recently been introduced as novel carriers for DNA/RNA delivery. The colloidal characteristics of the nanoparticles--particle size and surface charge--are considered the most significant determinants in the cellular uptake and trafficking of the nanoparticles. Therefore, our aim was to introduce chitosan-coated PLGA nanoparticles, whose size and charge are tunable to adapt for a specific task. The results showed that biodegradable nanoparticles as small as 130 nm and adjustable surface charge can be tailored controlling the process parameters. As a proof of concept, the overall potential of these particulate carriers to bind the antisense oligonucleotides, 2'-O-methyl-RNA, and improve their cellular uptake was demonstrated. The study proved the efficacy of chitosan-coated PLGA nanoparticles as a flexible and efficient delivery system for antisense oligonucleotides to lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692575     DOI: 10.1016/j.nano.2007.03.006

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  55 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 2.  Methods for the preparation and manufacture of polymeric nanoparticles.

Authors:  Christine Vauthier; Kawthar Bouchemal
Journal:  Pharm Res       Date:  2008-12-24       Impact factor: 4.200

Review 3.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

4.  In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency.

Authors:  Azita J Mahiny; Alexander Dewerth; Lauren E Mays; Mohammed Alkhaled; Benedikt Mothes; Emad Malaeksefat; Brigitta Loretz; Jennifer Rottenberger; Darina M Brosch; Philipp Reautschnig; Pacharapan Surapolchai; Franziska Zeyer; Andrea Schams; Melanie Carevic; Martina Bakele; Matthias Griese; Matthias Schwab; Bernd Nürnberg; Sandra Beer-Hammer; Rupert Handgretinger; Dominik Hartl; Claus-Michael Lehr; Michael S D Kormann
Journal:  Nat Biotechnol       Date:  2015-05-18       Impact factor: 54.908

5.  Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Authors:  Rajan Swami; Indu Singh; Wahid Khan; Sistla Ramakrishna
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

Review 6.  Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9.

Authors:  Hong-Xia Zhang; Ying Zhang; Hao Yin
Journal:  Mol Ther       Date:  2019-01-25       Impact factor: 11.454

Review 7.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

8.  Enhanced delivery of biodegradable mPEG-PLGA-PLL nanoparticles loading Cy3-labelled PDGF-BB siRNA by UTMD to rat retina.

Authors:  Jing DU; Ying Sun; Feng-Hua Li; Lian-Fang DU; You-Rong Duan
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

9.  Biodegradable starch derivatives with tunable charge density-synthesis, characterization, and transfection efficiency.

Authors:  Carolin Thiele; Brigitta Loretz; Claus-Michael Lehr
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

Review 10.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.